ReviewItalian journal of pediatrics2017
Denosumab treatment for progressive skull base giant cell tumor of bone in a 14 year old female - a case report and literature review.
Review in Italian journal of pediatrics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Denosumab for Effective Tumor Size Reduction in Patients With Giant Cell Tumors of the Bone: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Giant Cell Tumor of the Distal Humerus: A Rare Location With a Good Response to Denosumab.Cureus · 2026Article
- Article
- Giant cell tumor of the temporal bone: two case reports and literature review.Archives of craniofacial surgery · 2025Article
- A Rare Pediatric Giant Cell Tumor of the Clivus Bone, H3.3 p.Gly35Trp-mutated: Case Report and Mini-review of the Literature.Turkish archives of pediatrics · 2025Article
- Excellent Results in the Off-Label Use of Denosumab in Pediatric Oncology: Monocentric Case Series Study.Case reports in pediatrics · 2025Article
- Management of RANKL-mediated Disorders With Denosumab in Children and Adolescents: A Global Expert Guidance Document.The Journal of clinical endocrinology and metabolism · 2024Article
- Treatment of Clival Giant Cell Tumor: A Case Report and Literature Review.Brain tumor research and treatment · 2024Article
- Malignant Brain and Spinal Tumors Originating from Bone or Cartilage.Advances in experimental medicine and biology · 2023Article
- Role of denosumab before resection and reconstruction in giant cell tumors of bone: a single-centered retrospective cohort study.European journal of orthopaedic surgery & traumatology : orthopedie traumatologie · 2022Article
- Surgical management of giant cell tumor invading the occipital bone: A case report and literature review.Surgical neurology international · 2022Article
- Dosing interval adjustment of denosumab for the treatment of giant cell tumor of the sphenoid bone: A case report.Surgical neurology international · 2020Article
- Left orbital roof giant cell tumor of bone: A case report.Surgical neurology international · 2018Article
- Giant Cell Tumor: Changing Behavior from Intraorbital to Intraosseous Mass.Journal of current ophthalmologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGiant cell tumor of bone (GCT) is a rare primary bone tumor, which can metastasize and undergo malignant transformation. The standard treatment of GCT is surgery. In patients with unresectable or metastatic disease, additional therapeutic options are available. These include blocking of the receptor activator of NF-kappa B ligand (RANKL) signaling pathway, which plays a role in the pathogenesis of GCT of bone, via the anti-RANKL monoclonal antibody denosumab. CASE PRESENTATION: Herein we report on a female teenager who presented in a very poor clinical condition (cachexia, diplopia, strabismus, dysphonia with palsy of cranial nerves V, VI, VIII, IX, X, XI and XII) due to progressive disease, after incomplete resection and adjuvant radiotherapy, of a GCT which affected the cervical spine (C1 and C2) as well as the skull base; and who had an impressive clinical response to denosumab therapy. To the best of our knowledge, this is the youngest patient ever reported with a skull base tumor treated with denosumab.
conclusionIn situations when surgery can be postponed and local aggressiveness of the tumor does not urge for acute surgical intervention, upfront use of denosumab in order to reduce the tumor size might be considered. Principally, the goal of denosumab therapy is to reduce tumor size as much as possible, with the ultimate goal to make local surgery (or as in our case re-surgery) amenable. However, improvement in quality of life, as demonstrated in our patient, is also an important aspect of such targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.